At a recent symposium, William Rigby, MD, discussed the unprecedented efficacy of chimeric antigen receptor T-cell therapy in lupus patients, reporting almost complete disappearance of symptoms. However, long-term impacts remain to be seen, as B-cell responses eventually returned. Rigby presented findings from a study that showed that CAR-T cell therapy was more effective than other B-cell depleting therapies in rheumatic diseases. He also discussed the potential of CAR-T cell therapy in treating anti-synthetase syndrome and systemic sclerosis, but noted that there are still many questions about its feasibility and the long-term implications of the treatment. Despite these obstacles, Rigby believes that the data support further investigation and the therapy’s potential in rheumatic disease care.
Source link